Table 1.
Landmark Clinical Trials
| Trial | Checkpoint Inhibitor | Response | PFS | OS |
|---|---|---|---|---|
| KEYNOTE-012 (N=27) |
Pembrolizumab | ORR 18.5% | 1.9 months | 11.2 months |
| KEYNOTE-028 (N=25) |
Pembrolizumab | ORR 12% | 1.8 months | 8.6 months |
| KEYNOTE-086 Cohort A (N=170, 61.8% PD-L1+) |
Pembrolizumab | ORR 4.7% (4.8% for PD-L1+, 4.7% for PD-L1-) |
2 months | 8.9 months |
| KEYNOTE-086 Cohort B (N=84) |
Pembrolizumab | ORR 23.1% | 2.1 months | - |
| Emens et al (N=115) |
Atezolizumab | ORR 10% (12% for PD-L1+, 0% for PD-L1-) |
1.4 months | 8.9 months |
| JAVELIN (N=168) |
Avelumab | ORR 4.8% (3.3% for PD-L1+, 2.4% for PD-L1-) |
5.9 months | 8.1 months |
| IMPASSION 130 (N=912) |
Atezolizumab + nab-paclitaxel | ORR 56% | 7.2 months (7.5 months for PD-L1+) |
21.3 months (25 months for PD-L1+) |